October 2017 Cure GM1 Update

The first Cure GM1 Run/Walk was a great success!

A very special thank you to our board secretary Marilee Leishman for organizing a wonderful fundraiser and spreading a ton of awareness for Cure GM1!  All the net proceeds from the fundraiser will be put towards advancing GM1 Gangliosidosis medical research and saving children’s lives.

Below is an amazing image of Eli and Evan’s supporters who participated in the Run/Walk.  There are so many amazing photos and we were truly honored and humbled by the outpouring of support.

Here’s the final results and scorecard for the campaign.

 

Thank you from the bottom of our hearts for all the support and amazing generosity!

 

Research Highlights

We are truly fortunate that there are now multiple GM1 programs making genuine strides forward.  Cure GM1 wrote a letter of support for an NIH (National Institute of Health) grant for BioStrategies, LLC.  BioStrategies is a small company located in Arkansas and they are working on developing an enzyme replacement therapy for GM1.

Read the press announcement below on being awarded a $2.438M NIH grant!

Lentiviral Gene Therapy Showing Promise

Read the NY Times article below on advances in gene therapy treating a brain disease called ALD (adrenoleukodystrophy).  These amazing results were achieved using a gene therapy technique that we are currently funding for GM1 Gangliosidosis at UC Davis.

In a First, Gene Therapy Halts a Fatal Brain Disease

 

In Memoriam

Augusto Barreiros Ribeiro from Brazil 01/21/2014-09/26/2017, lived 3 years, 8 months, and 5 days and fought valiantly against infantile GM1 Gangliosidosis.

Every Donation Matters

Your donation today will help save children’s lives.

Donate-Button

All donations are tax exempt and we will send you a receipt for your tax records so long as the necessary contact information is provided.  There are no paid employees at Cure GM1 and the maximum amount humanly possible is being put towards saving children’s lives.

October 2017 Cure GM1 Update

Leave a Reply